| 318.83 -4.36 (-1.35%) | 04-30 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 412.04 | 1-year : | 481.27 |
| Resists | First : | 352.77 | Second : | 412.04 |
| Pivot price | 331.3 |
|||
| Supports | First : | 302.82 | Second : | 271.94 |
| MAs | MA(5) : | 327.95 |
MA(20) : | 326.86 |
| MA(100) : | 306.56 |
MA(250) : | 169.47 |
|
| MACD | MACD : | 3.9 |
Signal : | 5.9 |
| %K %D | K(14,3) : | 22.3 |
D(3) : | 38.5 |
| RSI | RSI(14): 47.8 |
|||
| 52-week | High : | 356 | Low : | 34.89 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ PRAX ] has closed above bottom band by 20.3%. Bollinger Bands are 28.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 330.61 - 332.22 | 332.22 - 333.8 |
| Low: | 311.95 - 313.93 | 313.93 - 315.88 |
| Close: | 315.15 - 318.3 | 318.3 - 321.4 |
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
Thu, 30 Apr 2026
Praxis (NASDAQ: PRAX) details 2026 virtual meeting, director slate and Say-on-Pay - Stock Titan
Thu, 30 Apr 2026
Vanguard (NASDAQ: PRAX) reports 1.42M shares, 5.09% stake in Praxis - Stock Titan
Wed, 29 Apr 2026
Optimism Surrounds Praxis Precision Medicines (PRAX) Amid Potential FDA Approval for Ulixacaltamide - Yahoo Finance
Mon, 27 Apr 2026
Praxis Precision Medicines Inc. (PRAX): Rare Triple-Catalyst Setup in Neurology - Yahoo Finance
Tue, 14 Apr 2026
FDA starts Praxis review for essential tremor drug, decision due Jan. 2027 - Stock Titan
Tue, 14 Apr 2026
Praxis Precision gets FDA review for lead asset (PRAX:NASDAQ) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 28 (M) |
| Shares Float | 26 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 107 (%) |
| Shares Short | 3,950 (K) |
| Shares Short P.Month | 3,790 (K) |
| EPS | -13.49 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 34.84 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -28.7 % |
| Return on Equity (ttm) | -45.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -9.6 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -11.71 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -249 (M) |
| Levered Free Cash Flow | -146 (M) |
| PE Ratio | -23.64 |
| PEG Ratio | 0 |
| Price to Book value | 9.14 |
| Price to Sales | 0 |
| Price to Cash Flow | -35.66 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|